In a report released today, Ritu Baral from Cowen & Co. maintained a Buy rating on Trevena Inc (NASDAQ: TRVN), with a price target of $10. The company’s shares opened today at $1.86.
According to TipRanks.com, Baral is a top 100 analyst with an average return of 33.2% and a 57.9% success rate. Baral covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Allena Pharmaceuticals Inc, and Ionis Pharmaceuticals Inc.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Trevena Inc with a $10.67 average price target, implying a 473.7% upside from current levels. In a report issued on August 20, JMP Securities also maintained a Buy rating on the stock with a $15 price target.
.
See today’s analyst top recommended stocks >>
Based on Trevena Inc’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $9.3 million. In comparison, last year the company had a GAAP net loss of $20.43 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Trevena, Inc. is a clinical stage biopharmaceutical company, which engages in the provision of healthcare services and development of therapies. The company product pipeline consists of Olinvo, TRV250, and TRV734.
Read More on TRVN:
